中文摘要：

目的系统评价西格列汀治疗2型糖尿病的药理作用。方法计算机检索Cochrane图书馆（2014年第3期）、中国期刊全文数据库、中国生物医学文献数据库、万方数据库资源系统、维普数据库资源系统、Elsevier-Science Direct、牛津期刊数据库、英国医学期刊、Pub Med、医学文摘资料库、循证医学等中英文生物医学数据库。检索时限均从2006年1月至2014年10月,收集关于西格列汀的药理作用的随机对照试验,进行Meta分析。结果纳入9个随机对照试验,共3 284例患者。Meta分析结果显示：西格列汀组相比安慰剂组,能够轻度增加患者体重,但差异无统计学意义[加权均数差0.26,95%可信区间（-0.10,0.62）,P=0.16];西格列汀增强胰岛β细胞功能效果优于安慰剂组,差异有统计学意义[加权均数差11.02,95%可信区间（7.96,14.09）,P〈0.000 01];西格列汀的胃肠道反应发生率低于安慰剂组,差异无统计学意义[相对危险度0.95,95%可信区间（0.69,1.29）,P=0.73]。结论西格列汀治疗2型糖尿病患者,能够增强胰岛β细胞活性,没有明显的增加体重作用,且无明显胃肠道不良反应,它为2型糖尿病患者提供了一种新的、有效合理的选择。

英文摘要：

Objective The aim of this meta analysis is to assess pharmacological effect of Sitagliptin in the treatment of type 2 diabetes mellitus. Methods Databases including The Cochrane Library（Issue 3, 2014）, CNKI, CBM,Wan Fang data, VIP, Elsevier-Science Direct, Oxford Journal, BMJ, Pub Med, EMBASE, EBM and so on were electronically searched to collect the random controlled trials about the pharmacological effect of Sitagliptin, with the retrieval time from January 2006 to October 2014, and meta-analysis was performed. Result In all, 9 studies involving3 284 participants were included. The results of meta-analysis showed that： Compared with placebo, Sitagliptin caused slight weight gain, the difference has no statistical significance [WMD=0.26, 95%CI（-0.10,0.62）, P=0.16]; Sitagliptin increased the function of insulin β cell compared with placebo, and the difference has statistical significance [WMD=11. 02, 95 % CI（ 7. 96, 14. 09）, P〈0. 000 01 ]; there was also no statistically significant difference in the risk of gastrointestinal adverse event with Sitagliptin, compared to placebo [RR =0.95, 95% CI（0.69,1.29）, P =0.73].Conclusion For the patients of type 2 diabetes mellitus, Sitagliptin can increase the function of beta cell of islet,it also has no obvious weight gain,and it has no obvious gastrointestinal reaction,so it can provide a new reasonable choice for the patients of type 2 diabetes mellitus.